Are two binding sites better than one?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

A new study using x-ray crystallography has shown that the investigational agent matuzumab binds to EGFR at a different site than cetuximab (Erbitux).

PHILADELPHIA-A new study using x-ray crystallography has shown that the investigational agent matuzumab binds to EGFR at a different site than cetuximab (Erbitux). Their binding does not overlap, and they can bind to EGFR at the same time, Kathryn Ferguson, PhD, of the University of Pennsylvania School of Medicine, reported in Cancer Cell (13:365-373, 2008). The finding suggests the possibility of a new combination therapy for certain types of cancer, including colorectal cancer. Matuzumab is being developed by Merck KGaA.

 

Articles in this issue
Immunotherapy agent promising in NSCLC
NCCN greenlights nilotinib for imatinib-resistant CML patients
No overall survival benefit for dose-intense regimen in SCLC
Make a note of new smoking cessation codes
Relistor for treating OIC
Experts argue against need for phase III proton Rx trials
Spotlight on Cancer Centers
Novel peptide vaccine promising in myeloid leukemia
Masters of hematology and oncology: Father of tamoxifen a Brit to the core
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALL
Relapsing DLBCL patients respond to rituximab-based Rx
Who’s News
From the Editor
New compound inhibits Src family kinases
Are two binding sites better than one?
Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Data from the BL-B01D1-301 study support iza-bren as a potential standard of care for pretreated recurrent or metastatic nasopharyngeal carcinoma.

Iza-Bren Increases Responses in Recurrent Nasopharyngeal Carcinoma

Jonah Feldman
October 19th 2025
Article

Data from the BL-B01D1-301 study support iza-bren as a potential standard of care for pretreated recurrent or metastatic nasopharyngeal carcinoma.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.

Ivonescimab Combo Boosts PFS in Advanced Squamous NSCLC Trial

Kristi Rosa
October 19th 2025
Article

Data from the phase 3 HARMONi-6 study may support ivonescimab plus chemotherapy as a new standard of care in advanced squamous non–small cell lung cancer.

The investigator-evaluated ORR was 39.0% among those treated for recurrent/metastatic HNSCC, and the CR and PR rates were 9.8% and 29.3%, respectively.

Enfortumab Vedotin/Pembrolizumab Display Frontline Efficacy in PD-L1+ HNSCC

Jax DiEugenio
October 19th 2025
Article

The investigator-evaluated ORR was 39.0% among those treated for recurrent/metastatic HNSCC, and the CR and PR rates were 9.8% and 29.3%, respectively.